Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Eur J Med Genet ; 64(9): 104264, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34161864

RESUMEN

BACKGROUND: Maturity onset diabetes of the young (MODY) is the most commonly reported form of monogenic diabetes in the pediatric population. Only a few cases of digenic MODY have been reported up to now. CASE REPORT: A female patient was diagnosed with diabetes at the age of 7 years and was treated with insulin. A strong family history of diabetes was present in the maternal side of the family. The patient also presented hypomagnesemia, glomerulocystic kidney disease and a bicornuate uterus. Genetic testing of the patient revealed that she was a double heterozygous carrier of HNF1A gene variant c.685C > T; (p.Arg229Ter) and a whole gene deletion of the HNF1B gene. Her mother was a carrier of the same HNF1A variant. CONCLUSION: Digenic inheritance of MODY pathogenic variants is probably more common than currently reported in literature. The use of Next Generation Sequencing panels in testing strategies for MODY could unmask such cases that would otherwise remain undiagnosed.


Asunto(s)
Diabetes Mellitus Tipo 2/genética , Factor Nuclear 1-alfa del Hepatocito/genética , Factor Nuclear 1-beta del Hepatocito/genética , Enfermedades Renales Quísticas/genética , Enfermedades Renales/genética , Defectos Congénitos del Transporte Tubular Renal/genética , Niño , Diabetes Mellitus Tipo 2/patología , Femenino , Heterocigoto , Humanos , Enfermedades Renales/patología , Enfermedades Renales Quísticas/patología , Mutación , Fenotipo , Defectos Congénitos del Transporte Tubular Renal/patología , Útero/anomalías
2.
J Clin Endocrinol Metab ; 106(6): 1742-1749, 2021 05 13.
Artículo en Inglés | MEDLINE | ID: mdl-33570564

RESUMEN

CONTEXT: Collagens are the most abundant proteins in the human body. In a growth plate, collagen types II, IX, X, and XI are present. Defects in collagen genes cause heterogeneous syndromic disorders frequently associated with short stature. Less is known about oligosymptomatic collagenopathies. OBJECTIVE: This work aims to evaluate the frequency of collagenopathies in familial short stature (FSS) children and to describe their phenotype, including growth hormone (GH) treatment response. METHODS: Eighty-seven FSS children (pretreatment height ≤ -2 SD both in the patient and his or her shorter parent) treated with GH were included in the study. Next-generation sequencing was performed to search for variants in the COL2A1, COL9A1, COL9A2, COL9A3, COL10A1, COL11A1, and COL11A2 genes. The results were evaluated using American College of Medical Genetics and Genomics guidelines. The GH treatment response of affected children was retrospectively evaluated. RESULTS: A likely pathogenic variant in the collagen gene was found in 10 of 87 (11.5%) children. Detailed examination described mild asymmetry with shorter limbs and mild bone dysplasia signs in 2 of 10 and 4 of 10 affected children, respectively. Their growth velocity improved from a median of 5.3 cm/year to 8.7 cm/year after 1 year of treatment. Their height improved from a median of -3.1 SD to -2.6 SD and to -2.2 SD after 1 and 3 years of therapy, respectively. The final height reached by 4 of 10 children differed by -0.67 to +1.0 SD and -0.45 to +0.5 SD compared to their pretreatment height and their affected untreated parent's height, respectively. CONCLUSION: Oligosymptomatic collagenopathies are a frequent cause of FSS. The short-term response to GH treatment is promising.


Asunto(s)
Colágeno/genética , Trastornos del Crecimiento , Placa de Crecimiento/patología , Adolescente , Adulto , Niño , Preescolar , Colágeno/deficiencia , Colágeno Tipo XI/genética , República Checa/epidemiología , Bases de Datos Factuales , Femenino , Estudios de Asociación Genética , Trastornos del Crecimiento/tratamiento farmacológico , Trastornos del Crecimiento/epidemiología , Trastornos del Crecimiento/genética , Trastornos del Crecimiento/patología , Placa de Crecimiento/crecimiento & desarrollo , Placa de Crecimiento/metabolismo , Hormona de Crecimiento Humana/deficiencia , Hormona de Crecimiento Humana/uso terapéutico , Humanos , Masculino , Fenotipo , Estudios Retrospectivos , Adulto Joven
3.
J Clin Endocrinol Metab ; 105(3)2020 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-31990356

RESUMEN

CONTEXT: The C-type natriuretic peptide receptor encoded by the NPR2 gene is a paracrine regulator of the growth plate; heterozygous NPR2 variants cause short stature with possible presence of different signs of bone dysplasia. To date, the effect of growth hormone (GH) treatment has been described in a few individuals with NPR2 gene variants with inconsistent results. OBJECTIVES: To identify NPR2 gene variants among children with familial short stature (FSS) and to describe their phenotype, including GH treatment response. DESIGN, SETTINGS AND PATIENTS: Out of 747 patients with short stature treated with GH in a single center, 87 with FSS met the inclusion criteria (pretreatment height ≤ -2 standard deviation in both the patient and the shorter parent, unknown genetic etiology). Next-generation sequencing methods were performed to search for NPR2 gene variants. The results were evaluated using the American College of Medical Genetics and Genomics guidelines. The GH treatment response (growth velocity improvement and height standard deviation score development over the first 5 years of treatment) was evaluated. RESULTS: In 5/87 children (5.7%), a (likely) pathogenic variant in the NPR2 gene was identified (p.Ile558Thr [in 2], p.Arg205*, p.Arg557His, p.Ser603Thr). Two children had disproportionate short-limbed short stature, 1 a dysplastic 5th finger phalanx. The growth velocity in the first year of GH treatment accelerated by 3.6 to 4.2 cm/year; the height improved by 1.2 to 1.8 SD over 5 years of treatment. CONCLUSIONS: NPR2 gene variants cause FSS in a significant proportion of children. Their GH treatment response is promising. Studies including final height data are necessary to assess the long-term efficacy of this therapy.


Asunto(s)
Estatura/genética , Enanismo/tratamiento farmacológico , Enanismo/genética , Hormona de Crecimiento Humana/administración & dosificación , Polimorfismo de Nucleótido Simple , Receptores del Factor Natriurético Atrial/genética , Adolescente , Adulto , Biomarcadores/análisis , Estatura/efectos de los fármacos , Niño , Preescolar , Estudios de Cohortes , Enanismo/patología , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Fenotipo , Pronóstico , Adulto Joven
4.
Pediatr Endocrinol Rev ; 16(1): 171-177, 2018 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30371035

RESUMEN

Overgrowth syndromes are rare genetic disorders characterized by excessive pre- and postnatal growth accompanied by dysmorphic features and developmental disorders. In addition to other health hazards, the life expectancy of affected children may be compromised due to an increased risk of developing tumors. To demonstrate the need for early recognition, correct diagnostic evaluation and adequate follow-up, we present a family with recurrent Simpson-Golabi-Behmel syndrome (SGBS). SGBS is a X-linked neonatal overgrowth syndrome caused by mutations in the GPC3 or GPC4 genes. All three affected males manifested with congenital diaphragmatic hernia. When fetal overgrowth and congenital diaphragmatic hernia co-occur, the choice for a possible cause is limited among SGBS, Marfan syndrome and Pallister-Killian syndrome. Their different phenotypes allow clinical assessment and correct diagnosis in most cases and should be followed by genetic testing. Regular oncologic screening aimed towards early recognition of malignant tumors may improve long-term outcomes in SGBS as well as in all other overgrowth syndromes.


Asunto(s)
Enfermedades Genéticas Ligadas al Cromosoma X , Gigantismo , Arritmias Cardíacas , Glipicanos , Cardiopatías Congénitas , Humanos , Recién Nacido , Discapacidad Intelectual , Masculino
5.
Ann Hum Genet ; 82(1): 48-51, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28940454

RESUMEN

The 17q12 chromosomal region carries the HNF1B gene, mutations of which cause various conditions. When searching for HNF1B/17q12 rearrangements among children with biliary atresia and/or choledochal cysts, we identified a male proband carrying a 17q12 duplication spanning 1698 kb that included 24 genes from TBC1D3C to HNF1B. The boy presented with cholestatic jaundice at the age of 2 weeks due to a choledochal cyst sized 15 ×12 mm (type Ia according to the Todani classification). He underwent a shunt surgery consisting of a hepaticojejunostomy using Roux-en-Y loop at the age of 2 months, which led to a permanent relief of cholestasis. Perioperative liver histology revealed significant hepatic fibrosis and bile ductular proliferation. At 17 years, he has a mildly enlarged liver with decreased elasticity, an upper-normal-sized spleen, normal biochemistry values, and no renal or hepatic cysts. We report the first hepatobiliary phenotype in a patient with an HNF1B overdosage.


Asunto(s)
Quiste del Colédoco/genética , Duplicación Cromosómica , Dosificación de Gen , Factor Nuclear 1-beta del Hepatocito/genética , Anastomosis en-Y de Roux , Cromosomas Humanos Par 17/genética , Humanos , Recién Nacido , Yeyuno/cirugía , Hígado/cirugía , Cirrosis Hepática/patología , Masculino
6.
J Pediatr Endocrinol Metab ; 30(12): 1311-1315, 2017 Nov 27.
Artículo en Inglés | MEDLINE | ID: mdl-29127764

RESUMEN

BACKGROUND: Congenital hyperinsulinism (CHI) is frequently caused by mutations in one of the KATP channel subunits encoded by the genes ABCC8 and KCNJ11. The effect of simultaneous mutations in both of these genes on the pancreatic ß-cell function is not known and patients with CHI carrying both ABCC8 and KCNJ11 mutations have not yet been reported. We questioned if a combination of heterozygous mutations in the ABCC8 and KCNJ11 genes could also lead to ß-cell dysfunction presenting as CHI. METHODS: As a model, we used a patient with transient CHI that paternally inherited novel heterozygous mutations in ABCC8 (p.Tyr1293Asp) and KCNJ11 (p.Arg50Trp) genes. The pathogenic effects on the pancreatic ß-cells function were examined in an in vitro functional study using radioactive rubidium efflux assay. RESULTS: We showed that the activation of the mutated KATP channels by diazoxide was decreased by 60.9% in the channels with the heterozygous combination of both mutations compared to the wild type channels. This could indicate the pathogenic effect on the pancreatic ß-cell function leading to CHI although conclusive evidence is needed to be added. CONCLUSIONS: Our findings may widen the spectrum of genetic causes of CHI and suggest a novel pathogenic mechanism of CHI that must however, be further investigated.


Asunto(s)
Hiperinsulinismo Congénito/genética , Canales de Potasio de Rectificación Interna/genética , Receptores de Sulfonilureas/genética , Adulto , Anciano , Niño , Preescolar , Hiperinsulinismo Congénito/fisiopatología , Epistasis Genética/fisiología , Familia , Heterocigoto , Humanos , Recién Nacido , Células Secretoras de Insulina/patología , Células Secretoras de Insulina/fisiología , Masculino , Persona de Mediana Edad , Herencia Multifactorial/genética , Mutación , Linaje
7.
Cas Lek Cesk ; 156(5): 233-240, 2017.
Artículo en Checo | MEDLINE | ID: mdl-28992707

RESUMEN

Novel genetic findings allow to more reliably elucidate the aetiology and pathogenesis of overgrowth syndromes in children and in adults. The relatively prevalent overgrowth syndromes in foetuses and neonates include Beckwith-Wiedemann (BWS) and Sotos syndromes; in addition, several rare conditions may occur e.g. Simpson-Golabi-Behmel and Weaver syndromes. These syndromes are not connected with overproduction of growth hormone. Their carriers are at risk of hypoglycaemia (in BWS), of congenital malformations and of childhood tumours. Targeted oncologic screening may improve the outcomes. Despite rapid growth even postnatally, the final height is mostly normal. In childhood and adolescence, the increased growth velocity results from hormonal overproduction - of precocious production of sexual hormones, hyperthyroidism, or of growth hormone overproduction due to pituitary adenoma that may lead to gigantism or acrogigantism and may be familiar (familiar isolated pituitary adenoma; FIPA). In 15-25 % of affected families, FIPA is caused by autosomal dominantly inherited mutations of AIP gene encoding a tumour suppressor protein named AIP (aryl hydrocarbon receptor-interacting protein). X-linked acrogigantism (X-LAG) is due to GPR101 gene mutations or microduplications of Xq26 chromosomal region. GPR101 encodes G-protein coupled receptor with unknown ligand. X-LAG is associated with recurrent and highly-penetrant pituitary macroadenomas. Mutations of additional at least 10 genes may lead to pituitary tumour with growth hormone overproduction. Gigantism in adults results from untreated or insufficiently treated pituitary adenoma in childhood. Some of the well-known current or past giants were found to carry pathogenic genetic variants of GPR101 or AIP.


Asunto(s)
Acromegalia , Adenoma , Gigantismo , Neoplasias Hipofisarias , Acromegalia/genética , Adenoma/genética , Adolescente , Adulto , Niño , Gigantismo/genética , Humanos , Mutación , Fenotipo , Neoplasias Hipofisarias/genética
8.
Horm Res Paediatr ; 88(2): 160-166, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28253502

RESUMEN

BACKGROUND: Germline STAT3 gain-of-function (GOF) mutations cause multiple endocrine and haematologic autoimmune disorders, lymphoproliferation, and growth impairment. As the JAK-STAT pathway is known to transduce the growth hormone (GH) signalling, and STAT3 interacts with STAT5 in growth regulation, we hypothesised that short stature in STAT3 GOF mutations results mostly from GH insensitivity via involving activation of STAT5. CASE REPORT: A boy with a novel STAT3 c.2144C>T (p.Pro715Leu) mutation presented with short stature (-2.60 SD at 5.5 years). He developed diabetes mellitus at 11 months, generalised lympho-proliferation, autoimmune thyroid disease, and immune bicytopenia in the subsequent years. At 5.5 years, his insulin-like growth factor-1 (IGF-I) was 37 µg/L (-2.22 SD) but stimulated GH was 27.7 µg/L. Both a standard IGF-I generation test (GH 0.033 mg/kg/day sc; 4 days) and a high-dose prolonged IGF-I generation test (GH 0.067 mg/kg/day sc; 14 days) failed to significantly increase IGF-I levels (37-46 and 72-87 µg/L, respectively). The boy underwent haematopoietic stem cell transplantation at 6 years due to severe neutropenia and massive lymphoproliferation, but unfortunately deceased 42 days after transplantation from reactivated generalised adenoviral infection. CONCLUSIONS: Our findings confirm the effect of STAT3 GOF mutation on the downstream activation of STAT5 resulting in partial GH insensitivity. 
.


Asunto(s)
Enfermedades Autoinmunes/genética , Trastornos del Crecimiento/genética , Hormona de Crecimiento Humana/metabolismo , Mutación , Factor de Transcripción STAT3/genética , Transducción de Señal/genética , Enfermedades Autoinmunes/metabolismo , Niño , Preescolar , Resultado Fatal , Trastornos del Crecimiento/metabolismo , Humanos , Lactante , Recién Nacido , Masculino , Factor de Transcripción STAT3/metabolismo , Gemelos
9.
J Clin Endocrinol Metab ; 102(2): 460-469, 2017 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-27870580

RESUMEN

CONTEXT: Heterozygous mutations in the aggrecan gene (ACAN) cause autosomal dominant short stature with accelerated skeletal maturation. OBJECTIVE: We sought to characterize the phenotypic spectrum and response to growth-promoting therapies. PATIENTS AND METHODS: One hundred three individuals (57 females, 46 males) from 20 families with autosomal dominant short stature and heterozygous ACAN mutations were identified and confirmed using whole-exome sequencing, targeted next-generation sequencing, and/or Sanger sequencing. Clinical information was collected from the medical records. RESULTS: Identified ACAN variants showed perfect cosegregation with phenotype. Adult individuals had mildly disproportionate short stature [median height, -2.8 standard deviation score (SDS); range, -5.9 to -0.9] and a history of early growth cessation. The condition was frequently associated with early-onset osteoarthritis (12 families) and intervertebral disc disease (9 families). No apparent genotype-phenotype correlation was found between the type of ACAN mutation and the presence of joint complaints. Childhood height was less affected (median height, -2.0 SDS; range, -4.2 to -0.6). Most children with ACAN mutations had advanced bone age (bone age - chronologic age; median, +1.3 years; range, +0.0 to +3.7 years). Nineteen individuals had received growth hormone therapy with some evidence of increased growth velocity. CONCLUSIONS: Heterozygous ACAN mutations result in a phenotypic spectrum ranging from mild and proportionate short stature to a mild skeletal dysplasia with disproportionate short stature and brachydactyly. Many affected individuals developed early-onset osteoarthritis and degenerative disc disease, suggesting dysfunction of the articular cartilage and intervertebral disc cartilage. Additional studies are needed to determine the optimal treatment strategy for these patients.


Asunto(s)
Agrecanos/genética , Enanismo/genética , Mutación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antropometría/métodos , Braquidactilia/genética , Niño , Preescolar , Análisis Mutacional de ADN/métodos , Enanismo/tratamiento farmacológico , Femenino , Crecimiento/genética , Hormona del Crecimiento/uso terapéutico , Heterocigoto , Humanos , Lactante , Degeneración del Disco Intervertebral/genética , Desplazamiento del Disco Intervertebral/genética , Masculino , Persona de Mediana Edad , Osteocondritis Disecante/congénito , Osteocondritis Disecante/genética , Linaje , Fenotipo , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA